XBIT - NASDAQ

XBiotech Inc.

XBIT·NASDAQ

$2.39

-0.27%

HealthcareBiotechnology

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$72.98M

EPS-1.4900

P/E Ratio-1.61

Earnings Date05/14/2026

150.08M

Assets

-25%

3Y-39.0%

5Y-58.0%

10Y+124.0%

9.73M

Total Liabilities

-42%

3Y+71.0%

5Y+91.0%

10Y+22.0%

140.35M

Total Equity

-23%

3Y-42.0%

5Y-60.0%

10Y+138.0%

XBiotech Inc. Funding & Solvency Profile

XBIT · NASDAQ

Current Assets

Cash & Cash Equivalents125.55M

Net Receivables360.00K

Inventory0.00

Other Current Assets1.04M

Total Current Assets127 M

Non-Current Assets

Property, Plant & Equipment23.13M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets23 M

Total Assets

150.08M

Financial Health Analysis

Current Ratio

16.01x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.07x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

119 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

85% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

XBiotech Inc. Balance Sheet

XBIT • NASDAQ

XBiotech Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	125.6M	172.7M	200M	157.3M	237M	237.4M	714.6M	15.8M	31.8M	34.3M	91.1M	57.3M	7.2M	4.2M
Short-Term Investments	0.0	0.0	0.0	60.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	125.6M	172.7M	200M	217.5M	237M	237.4M	714.6M	15.8M	31.8M	34.3M	91.1M	57.3M	7.2M	4.2M
Net Receivables	360K	858K	935K	1.8M	9M	4.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	858K	0.0	0.0	0.0	4.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	360K	0.0	935K	1.8M	9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	934K	582K	1.7M	1.2M	1.6M	2.6M	2M	411K	449K	197K
Other Current Assets	1M	1M	760K	601K	0.0	83.8M	1.7M	1.2M	1.6M	2.6M	2M	324K	0.0	0.0
Total Current Assets	127M	174.6M	201.7M	219.8M	246.9M	325.9M	716.3M	17M	33.3M	36.9M	93M	58.1M	7.7M	4.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	23.1M	24.5M	24.9M	26.3M	28.3M	27.3M	25.2M	27.3M	29.6M	30.1M	16.3M	4.1M	3.4M	4.1M
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	-75M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	75M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	1.7M	1.1M	533K	443K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	-1.7M	-1.1M	0.0	75M	0.0	0.0	0.0	0.0	0.0	0.0	-4.1M
Total Non-Current Assets	23.1M	24.5M	24.9M	26.3M	28.3M	27.9M	100.6M	27.3M	29.6M	30.1M	16.3M	4.1M	3.4M	4.1M
Other Assets	0.0	0.0	0.0	0.0	-1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	150.1M	199.1M	226.6M	246.1M	275.2M	353.7M	816.9M	44.3M	63M	67.1M	109.4M	62.2M	11.1M	8.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.6M	2.2M	2.6M	2.4M	2.1M	2.5M	2.1M	1.7M	1.7M	4.4M	4.8M	1.6M	561K	457K
Accounts Payable	1.5M	2.2M	2.5M	2.4M	2.1M	2.5M	2.1M	1.7M	1.7M	4.4M	4.8M	1.6M	561K	457K
Other Payables	76K	0.0	83K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	2M	2.9M	489K	480K	443K	337K	1.3M	1.1M	3M	1M	1.5M	284K	449K
Short Term Debt	0.0	10.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	76K	1.7M	83K	55K	10K	142K	49.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	4.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	6.3M	611K	562K	1.2M	904K	1.1M	53.2M	0.0	0.0	521K	421K	0.0	0.0	161K
Total Current Liabilities	7.9M	15.1M	6.1M	4.1M	3.5M	4M	60.2M	2.9M	2.8M	8M	6.3M	3.1M	845K	1.1M
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	5K	0.0	0.0	59K	873K	0.0	446K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.8M	1.7M	1.7M	1.6M	1.5M	1.1M	1.1M	3K	18K	23K	17K	0.0	0.0	29K
Total Non-Current Liabilities	1.8M	1.7M	1.7M	1.6M	2.3M	1.1M	1.1M	3K	18K	23K	17K	0.0	0.0	30K
Capital Lease Obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K
Total Liabilities	9.7M	16.8M	7.8M	5.7M	5.8M	5.1M	61.2M	2.9M	2.8M	8M	6.3M	3.1M	845K	1.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	134K
Common Stock	276.7M	273.1M	271.2M	267.3M	262.3M	249.8M	324.8M	279.4M	277.5M	242.4M	233.9M	152.4M	81.8M	69M
Additional Paid-In Capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	152.4M	81.8M	69M
Retained Earnings	-136.4M	-90.8M	-52.3M	-27.7M	5.2M	97.6M	430.9M	-237.7M	-216.6M	-183.4M	-130.7M	-93.2M	-71.4M	-61.5M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	826K	2M	1.3M	-106K	-255K	-768K	57K	-201K	-153K	-135K	-134K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-152.4M	-81.8M	-69M
Total Stockholders' Equity	140.4M	182.3M	218.8M	240.4M	269.4M	348.6M	755.6M	41.4M	60.2M	59.1M	103.1M	59M	10.2M	7.4M
Total Equity	140.4M	182.3M	218.8M	240.4M	269.4M	348.6M	755.6M	41.4M	60.2M	59.1M	103.1M	59M	10.2M	7.4M
SUMMARY
Total Liabilities & Equity	150.1M	199.1M	226.6M	246.1M	275.2M	353.7M	816.9M	44.3M	63M	67.1M	109.4M	62.2M	11.1M	8.5M
Total Investments	0.0	0.0	0.0	60.2M	0.0	0.0	75M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	0.0	10.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K
Net Debt	-125.6M	-162.4M	-200M	-157.3M	-237M	-237.4M	-714.6M	-15.8M	-31.8M	-34.3M	-91.1M	-57.3M	-7.2M	-4.2M
Shares Outstanding	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731	30,487,731

SEC Filings

XBIT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 29, 2026	December 31, 2025	2025	View Filing
10-K 10-K 2025 FY FY	March 13, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 09, 2025	December 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	October 15, 2025	June 24, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 03, 2025	October 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 02, 2025	August 29, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 13, 2025	June 30, 2025	2025	View Filing
DEF 14A DEF 14A 2025 N/A	July 07, 2025	August 29, 2025	2025	View Filing

Showing 1 to 10 of 133 filings

Related Guides

Blog Categories

Continue your XBIT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.